BHP, Rio Tinto shares rise as peer Vale posts smaller-than-feared Q2 profit drop
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a biopharmaceutical company specializing in targeted radiotherapies, today unveiled promising preclinical results for its novel prostate cancer treatment, ATNM-400. The announcement comes as the company’s stock has shown strong momentum, gaining over 32% in the past week according to InvestingPro data. The company announced that ATNM-400 demonstrated a 99.8% tumor growth inhibition in preclinical prostate cancer models with a single dose.
The initial preclinical findings are set to be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago. ATNM-400, which employs the Actinium-225 (Ac-225) radioisotope, is a first-in-class radiotherapy designed to target prostate cancer cells by a different marker than the prostate-specific membrane antigen (PSMA), aiming to provide an alternative for patients who do not respond to current PSMA-targeting treatments like Novartis’ Pluvicto. With a strong current ratio of 10.25, InvestingPro data shows the company maintains robust liquidity to support its research initiatives.
Sandesh Seth, Chairman and CEO of Actinium, expressed optimism about the potential of ATNM-400 to address the high unmet need for patients with resistance to Pluvicto therapy. Seth highlighted the strong tumor control and tolerability observed in preclinical studies, as well as the selective tumor uptake and minimal normal tissue uptake demonstrated by biodistribution studies.
Preclinical models showed that ATNM-400 accumulated in tumors for up to 144 hours post-administration and induced dose-dependent cytotoxicity with limited absorption in healthy tissues. Small animal SPECT/CT imaging further confirmed selective tumor accumulation.
Actinium is advancing ATNM-400 with additional data expected from Pluvicto-resistant prostate cancer models. The company’s broader research and development focus includes several preclinical programs for solid tumor indications, leveraging its portfolio of 230 patents and patent applications related to targeted radiotherapies and the manufacture of Ac-225.
The information in this article is based on a press release statement from Actinium Pharmaceuticals, Inc. While the company maintains a "Fair" financial health rating according to InvestingPro, analysts have recently revised earnings expectations downward for the upcoming period. InvestingPro subscribers have access to 11 additional investment tips and comprehensive financial metrics for ATNM.
In other recent news, Actinium Pharmaceuticals has introduced ATNM-400, a new radiotherapy for prostate cancer, as part of its expanding clinical pipeline. The company is also advancing its lead product, Actimab-A, into a pivotal Phase 2/3 trial for relapsed or refractory acute myeloid leukemia (AML) and a Phase 1 trial for other myeloid malignancies. Actinium has secured a supply of the radioisotope Actinium-225 from Eckert & Ziegler to support its clinical trials both domestically and internationally. Additionally, Actinium has launched a new clinical trial in collaboration with the National Cancer Institute to evaluate a novel triplet combination therapy for newly diagnosed AML patients. The company reported promising results from a clinical trial of Actimab-A combined with CLAG-M chemotherapy for patients with relapsed or refractory AML, showing a median overall survival of 18.4 months. H.C. Wainwright analyst Joseph Pantginis has maintained a Buy rating on Actinium shares, citing positive feedback from a recent Key Opinion Leader event and the company’s financial stability, which is expected to support operations into mid-2027. Actinium’s strategic focus remains on addressing high unmet medical needs in AML and myeloid malignancies, with plans to expand its clinical trials and manufacturing capabilities throughout 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.